Prof. Gerald R. Fink, Ph.D., Co-Founder
Gerald R. Fink, Ph.D, a founding member of the Whitehead Institute for Biomedical Research and American Cancer Society, and Professor of Genetics at MIT, was Director of the Whitehead Institute from 1990-2001. Dr. Fink received his Ph.D. degree in Genetics from Yale University, did postdoctoral research at the National Institute of Health, and then served for 15 years on the faculty of Cornell University. He was elected a Member of the National Academy of Sciences in 1981, and a fellow of the American Academy of Arts and Sciences in 1984. In 1988, he was elected President of the Genetics Society of America and in 1996, Dr. Fink was elected a member of the American Academy of Microbiology and the Institute of Medicine. Among his honors and awards are the National Academy of Sciences/U.S. Steel Foundation Award in Molecular Biology, the Medal of the Genetics Society of America, the Hansen Foundation Award for Microbiological Research, the Wilber Lucius Cross Medal from the Yale Graduate School Association, and the Gruber Foundation International Award in Genetics.
K. Frank Austen, M.D.
Dr. K. Frank Austen attended Amherst College and Harvard Medical School and served his house staff training years at the Massachusetts General Hospital (MGH). He established an independent laboratory at the MGH in 1962 and moved to the Robert B. Brigham in 1966 to establish a Department of Rheumatology and Immunology which evolved into a department of the Brigham and Women’s Hospital (BWH). After chairing this Department for 25 years, he shifted to the AstraZeneca Professorship of Respiratory and Inflammatory Diseases with an appointment as Director of Inflammation & Allergic Diseases Research Section. Austen has pioneered many aspects of innate immunity/inflammation through an in-depth focus on the functions and regulation of arachidonic acid metabolism to the cysteinyl leukotrienes (cysLTs), the pathways for the development and phenotypic diversity of mast cells, and the pattern recognition path for activation of the alternative complement activating pathway which also serves to amplify the classical complement pathway. Austen was elected to the National Academy of Sciences and to the American Academy of Arts and Sciences in 1974 and as a foreign member of the Royal Society (UK) in 2004. He has served as President of the American Association of Immunologists, the American Academy of Allergy, Asthma and Immunology, and the American Association of Physicians.
Prof. Charles G. Drake, M.D. Ph.D.
Dr. Drake is an Associate Professor of Medical Oncology, Immunology, and Urology at the Johns Hopkins University of Medicine. Dr. Drake earned his M.D. degree from the University of Colorado Health Science Center and his Ph.D. from National Jewish Center for Immunology. He is Board Certified in internal medicine and medical oncology.
Prof. Drew M. Pardoll, M.D., Ph.D.
Drew M. Pardoll, M.D, Ph.D., is the Seraphim Professor of Medicine at The Johns Hopkins University. Dr. Pardoll is an internationally recognized authority in cancer immunology and immunotherapy. He is noted for demonstrating the central role of GM-CSF in stimulating dendritic cells in vivo. In addition, he is a co-inventor of cytokine-gene-transduced tumor vaccines that are currently in clinical trials. Dr. Pardoll serves on the Scientific Advisory Board of Cerus, Jennerex, and Amplimmune, Inc. (of which he is a Founder).
Dr. Alan E. Smith, CBE, FRS, Ph.D.
Dr. Smith is the former Senior Vice President and the Chief Scientific Officer of Genzyme Corporation which he served from September 1996 until December 2011. Prior to Genzyme, Alan was the vice president and scientific director of Integrated Genetics, a company that was acquired by Genzyme in 1989. From October 1980 to October 1984, Dr. Smith served as Head of The Biochemistry Division of the National Institute for Medical Research, Mill Hill, London, England. Presently, Alan also sits on the Scientific Advisory Boards of the Massachusetts Life Science Center, The Cancer Research Institute in Cambridge UK and Pharnext, a start-up biotechnology company located in Paris, France and on the Board of Directors of Arecor, a start-up Biotechnology company in Cambridge UK and Cambridge in America, the representative body of Collegiate Cambridge UK. He holds a B.A. from Christ’s College, Cambridge and a Ph.D. from the Laboratory of Molecular Biology, Cambridge, England.